Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Name: Αlpha¹ Rigor Record — Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.
Item: Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.
Rating: 100
Author: Αlpha¹

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 2 high issues for “Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported double-blind RCT evaluating phentermine added to behavioral treatment in early nonresponders. The study design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria. Minor reporting inconsistencies (e.g., Cohen's d discrepancy) and a few clarity issues are present but do not undermine the overall integrity.

Both reviewers classified the study as interventional (RCT), and this was adopted. The evaluation covered the full text, with all eight dimensions applicable. Not-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 3 tests; other reported statistics were not machine-verified and should not be assumed correct.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple studies on behavioral treatment, early nonresponse, and anti-obesity medications, and clearly identifies the gap: no randomized trial has tested adding AOM to BT in early nonresponders. The rationale is well-articulated, and the study directly addresses this gap. Limitations of prior work are acknowledged, such as the lack of studies on rapid step-up approaches.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

direct quote[Introduction, paragraphs 1-4]

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”